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Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomized
trials versus other limus-eluting stents and an adjusted indirect comparison.
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Massimiliano Fusaro1, Adnan Kastrati1
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Background: The performance of zotarolimus-eluting stents (Medtronic Inc., Santa
Clara, CA, USA) versus other limus-eluting stents (LES) and the possible improvements
of Resolute zotarolimus-eluting stents (R-ZES) versus Endeavor zotarolimus-eluting
stents (E-ZES) still remain to be defined. We sought to evaluate efficacy and safety of two
zotarolimus-eluting stent generations versus other LES and to compare R-ZES versus
E-ZES.
Methods: We undertook a meta-analysis of trials in which patients were randomly
assigned to percutaneous coronary interventions (PCI) with R-ZES versus LES or with
E-ZES versus LES as well as an indirect comparison of R-ZES versus E-ZES, with LES
as common comparator. The primary efficacy endpoint was ischemia-driven target vessel
revascularization (ID-TVR); the primary safety endpoints were cardiac death and
cumulative definite/probable stent thrombosis (ST).
Results: Overall, 13,709 patients were assigned to PCI with R-ZES versus LES (n
7,185) or with E-ZES versus LES (n 6,524). The risk of ID-TVR (odds ratio [95%
confidence interval] 1.06 [0.90-1.25], p 0.47), cardiac death (0.99 [0.69-1.42], p
0.96) and ST (1.18 [0.68-2.03], p 0.56) did not differ between R-ZES and LES. Patients
receiving E-ZES were more likely to undergo ID-TVR as compared to those receiving
LES (1.95 [1.40-2.73], p0.0001). Cardiac death (1.02 [0.54-1.91], p 0.96) and ST
(1.10 [0.50-2.44], p 0.81) were similar between E-ZES and LES. At indirect compar-
ison, PCI with R-ZES versus E-ZES reduced the risk of ID-TVR (0.54 [0.37-0.78], p
0.001), without increasing cardiac death (0.97 [0.46-2.00], p 0.93) and ST (1.07
[0.40-2.80], p 0.88).
Conclusions: The antirestenotic efficacy of Resolute zotarolimus-eluting stents is
superior to Endeavor zotarolimus-eluting stents and similar to other limus-eluting stents.
Endeavor zotarolimus-eluting stents increase the risk of reinterventions as compared to
other limus-eluting stents. First and second zotarolimus-eluting stent generations have
similar thrombogenicity compared to other limus-eluting stents.
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Background: Vascular Inflammation plays a fundamental role in the process of
neointimal formation following coronary stent implantation. Drug-eluting stents (DES)
improve the efficacy of percutaneous coronary intervention by modulating vascular
inflammation. We aimed to evaluate the vascular inflammation profile following coronary
implantation of a novel stent comprising an abluminal biodegradable Everolimus-eluting
coating on the Element stent platform (SYNERGY) compared to an identical bare metal
stent control (BMS Element stent).
Methods: BMS (Element, n6) and SYNERGY (n6) stents were implanted in nine
8-month-old FH swine. Each coronary target site was predilated with an angioplasty
balloon prior to stent placement. At 30 days stents were analyzed with optical coherence
tomography (OCT) and then harvested for histological analysis and immunohistochem-
istry (MAC387: Macrophages; CD3: T-cells lymphocytes). Para strut leukocyte (PSL),
Foamy macrophage infiltration (FMI) and adventitial inflammation (AI) were evaluated in
a semi-quantitative score.
Results: Both OCT (neointimal area; SYNERGY, 3.680.8 mm2 vs. BMS, 5.70.8
mm2, 35% reduction) and histology (neointimal area; SYNERGY3.180.73 mm2 vs.
BMS 5.930.78 mm2, 46% reduction) demonstrated a significant reduction in
neointimal proliferation in the SYNERGY group. The SYNERGY stent exhibited
significant reduction in PSL (0.330.69) compared to BMS (2.390.7, p0.001). The
neointimal area occupied by foam cells was significantly greater in BMS (0.570.53
mm2) compared to SYNERGY group (0.280.35 mm2). Consistently, FMI score was
also decreased in SYNERGY (0.830.79) compared to BMS (2.442.06, p0.001). The
AI score, did not showed significant differences between the studied groups (SYNERGY
1.331.46, BMS 1.941.55; p0.15).
Conclusions: The abluminal-only Everolimus eluting SYNERGY stent demonstrated
suppression of neointimal formation and vascular inflammatory response compared to an
identical bare metal stent platform. The absence of polymer beyond the drug delivery
period creates the potential to reduce DAPT duration while maintaining best-in-class DES
efficacy.
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Background: Elderly patients (P) after bare metal stents (BMS) traditionally experience
higher rates of procedural complication and worse long-term outcomes compared to
younger P. This study sought to evaluate the long-term clinical follow-up (FU) after drug
elution stents (DES) in octogenarians compared to P60 y old and P 60-79 y old.
Methods: 4229 P were included in the DESIRE (Drug Elution Stents In The Real World)
Registry for an elective DES implantation between 05/2002 and 02/2012. They were
divided into 3 groups (g) according to their age: GI : 60 y (n;1,516 pts); GII:60-79 y
(n 2,397 pts); GIII:80 Y(n316 pts). The baseline and procedural characteristics as
well as the outcomes are in the table.














Mean age (y) 52,29 69,23 84,25 N/A
Female (%) 14,1 26* 43,3* 0.01
Diabetes (%) 24,6 34,8* 26,3 0.01
AMI Prior (%) 23,4 22,4 20,9 0.09
Hypertension (%) 69,3* 80,5 81,6 0.01
Hypercholesterolemia
(%)
64,6 62,9 52,5* 0.01
Unstable angina (%) 23,4 23 19* 0.03
Multivessel disease
(%)
59,9 65* 70,6* 0.04
Mean Follow-up(Y) 4,1-2,5 3,8-2,5 3,7-2,0 0.1
Cumulative MACE
Cardiac Death (%) 2,18 4,34 10,44* 0.01
Total MI 6,79 6,47 9,81* 0.02
TVR PCI (%) 5,15 3,21 1,58* 0.01
TVR CABG(%) 1,39 1,04 0 0.3
TVR(%) 6,33 4,13 1,58* 0.01
MACE (%) 22,6 21,0 24,0* 0.05
Conclusions: DES in octogenarians have a higher incidence of MACE(24%) due to
higher periprocedure MI and mortality rate and as compared to younger patients in a long
term follow-up. However, this incidence is far lower than the observed in the historical
series with BMS and CABG in the same population.
TCT-645
Comparison of Angiographic and Clinical Outcomes Among Patients with
Sirolimus-, Paclitaxel-, Zotarolimus-, and Everolimus-Eluting Stent
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Background: Stenting in small coronary artery and long lesions has been known for high
rates of clinical events. There has been no study comparing angiographic and long-term
clinical outcomes among stable angina patients with sirolimus-(SES,n285), paclitaxel-
(PES,n52), zotarolimus-(ZES,n93), and everolimus-eluting stent (EES,n170) im-
plantation in small coronary target vessels and long lesions.
Methods: Propensity matching was performed among 4 cohort groups, and coronary
lesions with reference diameter2.75mm and lesion length28mm were included. Late
loss and rates of in-stent restenosis at 9-month follow-up were compared, and major
adverse cardiovascular events(MACEs) such as all-cause death, non-fatal myocardial
infarction, stroke, and target lesion revascularization(TLR) were compared during the
3-year follow-up.
Results: Late loss was significantly lower in the EES group when compared with the PES
and ZES groups (0.340.14mm, 0.600.15mm 0.650.16mm, respectively, p0.05).
Rate of TLR was significantly lower in the in the EES group when compared with the
SES, PES and ZES groups (2.1%, 9.8%, 11.8%, 8.4%,respectively). Rates of MACE
during the 3-year follow-up were significantly lower in the EES. (Figure)
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Conclusions: Rate of MACEs was significantly lower in the EES group when compared
with the SES, PES, and ZES groups, mainly due to the lower rate of TLR during the
3-year follow-up.
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Background: Implantation of drug-eluting stents in long coronary artery lesions is
associated with a higher risk for restenosis and stent thrombosis related to the need for
multiple and overlapping stents. The Resolute zotarolimus-eluting stent (R-ZES) is
manufactured in a 38 mm length to accommodate longer lesions but clinical data to
demonstrate efficacy and safety of the longer stent have not been reported.
Methods: A substudy of 2 prospective, multicenter clinical trials; RESOLUTE–US and
RESOLUTE-Asia enrolled patients with de novo coronary artery lesions amenable to
treatment with the 38-mm-length R-ZES. The target lesion had to be  35 mm long and
the primary endpoint was target lesion failure (TLF) defined as the composite of cardiac
death, target vessel myocardial infraction (TVMI), or clinically-driven target lesion revascu-
larization (TLR) by percutaneous or surgical methods. The rate of TLF at 1 year was compared
to a performance goal of 19.0% based on literature suggesting an expected TLF rate of 15.1%.
All patients were prescribed dual antiplatelet therapy for a minimum of 6 months.
Results: There were 223 patients treated with a 38 mm R-ZES; mean age was 61 years,
78.9% were men, 44.6% were white, 3.6% were black, and 50.9% were Asian. Prior PCI
was noted in 27.4% of patients, 37.7% had diabetes mellitus and 53.8% had multivessel
disease. Lesions were located in the LAD (52.0%), LCX (20.2%) and RCA (44.4%) and
3.4% were moderately or severely torturous. TIMI flow was 0 or 1 in 6.1% of lesions and
47.9% were branch vessel disease with mean sidebranch stenosis of 30.4%; 91.2% were
lesion class B2/C. The primary endpoint was met with a 12-month TLF rate of 4.5%
(upper one-sided 95% confidence interval 7.5%). Rates of cardiac death, TVMI, and TLR
at 12 months were 0.9%, 3.6%, and 1.4% respectively. Early stent thrombosis (30 days)
was 0.9% and there were no stent thrombosis events after 30 days.
Conclusions: At 12 months the rate of TLF was significantly less than the performance
goal of 19% and clinical events rates were low with no late stent thrombosis. The 38 mm
length R-ZES was safe and effective in this selected population of long lesion patients.
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Background: Higher levels of high-density lipoprotein cholesterol (HDL-C) have been
associated with decreased cardiovascular risk in epidemiologic studies, although a causal
role is in question. Dysfunctional HDL has been identified in humans with metabolic
syndrome (MSx) or coronary artery disease (CAD). Additionally, current determinations
of HDL-C may not correlate with the true anti-atherosclerotic properties, casting doubts
on its prognostic value. Therefore, the significance of HDL-C on the outcome of patients
with CAD requiring percutaneous coronary intervention (PCI) is unclear.
Methods: Patients treated with PCI from 01/2004 to 12/2011 were prospectively
enrolled. The lipid panel of those on statin therapy prior to PCI and who had attained
low-density lipoprotein cholesterol (LDL-C) 100 mg/dl was analyzed. Major adverse
cardiac events (MACE), including all-cause death, Q-wave myocardial infarction, and
target vessel revascularization at 1 year were evaluated in relation to the lipid profile at the
time of index PCI. Multivariable Cox proportional hazards regression was employed for
the entire cohort and for the subgroup of patients with diabetes mellitus (DM) or MSx.
Results: 2759 patients were included. The population’s mean age was 66 years and 68%
was male. 53% had a history of CAD, 39.8% had DM and 42.5% had MSx. At 1-year
follow-up, a total of 279 patients (10.1%) experienced MACE. Death occurred in 5.2% of
the population. HDL-C after adjustment for baseline characteristics did not demonstrate
an independent association with MACE in either the main population or the subgroup
with MSx (HR 1.00, 95% CI 0.99-1.01, p0.98 and HR 1.00, 95% CI 0.99-1.01, p0.93,
respectively). However, the evaluation of non-HDL levels at the time of PCI demonstrated
a trend for the subgroup of patients with DM or MSx (HR 0.99, 95% CI 0.99-1.00,
p0.07).
Conclusions: In patients treated with statin therapy for CAD, in whom an LDL-C level
100 mg/dl has been achieved at the time of PCI; HDL-C did not independently correlate
with MACE at 1 year. These data suggest that HDL-C for patients on statin therapy and
controlled LDL may not be an effective biomarker for future clinical events.
TCT-648
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Nicolas Foin1, Nicola Viceconte2, Sayan Sen3, Sukhjinder Nijjer3,
Ricardo Petraco3, Carlo Di Mario3, Justin Davies3
1International Centre for Circulatory Health, Imperial College London, London,
United Kingdom, 2Royal Brompton Hospital, London, London, 3Imperial College
London, London, United Kingdom
Background: There are major differences in the structural design of currently available
coronary stents. Differences in radial forces have been reported between the different stent
platforms, but it is still unclear how stent material and strut design may affect stent
mechanical performances in clinical settings.
Methods: To evaluate coronary stent designs in a reproducible environment, we created
a compliant model of a focal coronary lesion, representing a 50% reduction in lumen
diameter. The stents evaluated were the Cobalt Chromium (CoCr) Xience V (Abbott
Vascular) and Integrity (Medtronic), 316L Stainless Steel (316L SS) Taxus Liberte
(Boston Scientific) and BioMatrix Flex (Biosensors Int.), and the Platinium Chromium
(PtCr) Promus Element (Boston Scientific). The 3.0 stents (n14) were deployed across
the model lesion at their Nominal Pressure (NP). Minimal Lumen Area (MLA), residual
% area stenosis and strut apposition were assessed at NP from micro-CT. After NP
assessment, the same 3.0 delivery balloon was then inflated at 18 ATM to evaluate impact
of deployment pressure on plaque recoil and residual stenosis. A total of 28 experiments
were performed.
Results: MLA was significantly increased with pressure deployment: from 5.0  0.5
mm2 at NP to 6.8  0.1 mm2 with 18 ATM dilatation (p0.001). This transposed in a
residual area stenosis reducing from an average of 23.7 % at NP to only -1.3 % (relative
to the reference vessel area) at 18 ATM (p0.0009). Higher pressure also elimated the
risk of mallaposed strut from a maximal cross-sectional rate of malapposed strut observed
of 25.6 % at NP compared to virtually zero malapposition at 18 ATM pressure. At NP,
CoCr stents resulted in overall higher MLA and lower residual stenosis than 316L SS and
PtCr stents, MLA was respectively 5.4 mm2 for CoCr, 4.9 mm2 for 316L SS and 5.0
mm2 for PtCr (p0.0001). Such differences were markedly eliminated with higher
pressure inflation: at 18 ATM, MLA was respectively 6.7 mm2 for CoCr, 6.6 mm2 for
316L SS and 6.8 mm2 for PtCr.
Conclusions: Initial results with 5 different DES designs underline the importance of
deployment pressure in the overall ability of a stent to scaffold a lesion and restore lumen
area.
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